FI64140C - Foerfarande foer framstaellning av nya terapeutiskt anvaendbara peptider - Google Patents

Foerfarande foer framstaellning av nya terapeutiskt anvaendbara peptider Download PDF

Info

Publication number: FI64140C
Authority: FI; Finland
Prior art keywords: group; solution; ile; pro; arg
Prior art date: 1977-07-18

Application number

FI782250A

Other languages

English (en)

Finnish (fi)

Other versions

FI782250A7 (fi

FI64140B (fi

Inventor

Lajos Kisfaludy

Gyoergy Nyeki

Laszlo Szirmai

Egon Karpati

Katalin Gidai

Laszlo Szporny

Original Assignee

Richter Gedeon Vegyeszet

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-07-18

Filing date

1978-07-14

Publication date

1983-10-10

1978-07-14 Application filed by Richter Gedeon Vegyeszet filed Critical Richter Gedeon Vegyeszet

1979-01-19 Publication of FI782250A7 publication Critical patent/FI782250A7/fi

1983-06-30 Publication of FI64140B publication Critical patent/FI64140B/fi

1983-10-10 Application granted granted Critical

1983-10-10 Publication of FI64140C publication Critical patent/FI64140C/fi

Links

229940126601 medicinal product Drugs 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 21
108090000765 processed proteins & peptides Proteins 0.000 claims description 18
-1 aminooxyacetyl Chemical group 0.000 claims description 12
102000004196 processed proteins & peptides Human genes 0.000 claims description 11
238000000034 method Methods 0.000 claims description 10
150000003839 salts Chemical class 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 8
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 6
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
125000006239 protecting group Chemical group 0.000 claims description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
229910052739 hydrogen Inorganic materials 0.000 claims description 4
239000001257 hydrogen Substances 0.000 claims description 4
125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 claims description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 3
230000003213 activating effect Effects 0.000 claims description 2
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 2
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 2
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
125000001239 threonyl group Chemical group 0.000 claims description 2
125000003277 amino group Chemical group 0.000 claims 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 96
239000000243 solution Substances 0.000 description 62
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 48
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 45
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 44
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 33
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 32
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
239000000203 mixture Substances 0.000 description 21
WBIIPXYJAMICNU-AWEZNQCLSA-N (2s)-5-[amino-[(4-methylphenyl)sulfonylamino]methylidene]azaniumyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate Chemical compound CC1=CC=C(S(=O)(=O)NC(N)=NCCC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C=C1 WBIIPXYJAMICNU-AWEZNQCLSA-N 0.000 description 14
239000000047 product Substances 0.000 description 14
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 13
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 13
229950006323 angiotensin ii Drugs 0.000 description 13
238000001704 evaporation Methods 0.000 description 12
230000008020 evaporation Effects 0.000 description 12
238000001035 drying Methods 0.000 description 11
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
229940024606 amino acid Drugs 0.000 description 10
235000001014 amino acid Nutrition 0.000 description 10
150000001413 amino acids Chemical class 0.000 description 10
239000002904 solvent Substances 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
101800000733 Angiotensin-2 Proteins 0.000 description 8
102400000345 Angiotensin-2 Human genes 0.000 description 8
229920002134 Carboxymethyl cellulose Polymers 0.000 description 8
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 8
235000010948 carboxy methyl cellulose Nutrition 0.000 description 8
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 7
206010020772 Hypertension Diseases 0.000 description 6
230000036772 blood pressure Effects 0.000 description 6
229910000040 hydrogen fluoride Inorganic materials 0.000 description 6
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
239000001768 carboxy methyl cellulose Substances 0.000 description 5
239000008112 carboxymethyl-cellulose Substances 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
238000001914 filtration Methods 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
108010010803 Gelatin Proteins 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
102100028255 Renin Human genes 0.000 description 4
108090000783 Renin Proteins 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
125000001931 aliphatic group Chemical group 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000003042 antagnostic effect Effects 0.000 description 4
239000003054 catalyst Substances 0.000 description 4
238000010511 deprotection reaction Methods 0.000 description 4
230000000694 effects Effects 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
239000007788 liquid Substances 0.000 description 4
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 4
AYMLQYFMYHISQO-QMMMGPOBSA-N (2s)-3-(1h-imidazol-3-ium-5-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CN=CN1 AYMLQYFMYHISQO-QMMMGPOBSA-N 0.000 description 3
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
239000005695 Ammonium acetate Substances 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
229940043376 ammonium acetate Drugs 0.000 description 3
235000019257 ammonium acetate Nutrition 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000002955 isolation Methods 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
LHMQOAPYTSAHML-LBPRGKRZSA-N (2,3,4,5,6-pentafluorophenyl) (2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate Chemical compound CC(C)(C)OC(=O)N[C@@H](C(C)C)C(=O)OC1=C(F)C(F)=C(F)C(F)=C1F LHMQOAPYTSAHML-LBPRGKRZSA-N 0.000 description 2
CNBUSIJNWNXLQQ-NSHDSACASA-N (2s)-3-(4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNBUSIJNWNXLQQ-NSHDSACASA-N 0.000 description 2
108010016626 Dipeptides Proteins 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
108010083387 Saralasin Proteins 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
QFYBYZLHPIALCZ-ZETCQYMHSA-N eglu Chemical compound CC[C@@](N)(C(O)=O)CCC(O)=O QFYBYZLHPIALCZ-ZETCQYMHSA-N 0.000 description 2
238000010828 elution Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
238000002844 melting Methods 0.000 description 2
NYIODHFKZFKMSU-UHFFFAOYSA-N n,n-bis(methylamino)ethanamine Chemical compound CCN(NC)NC NYIODHFKZFKMSU-UHFFFAOYSA-N 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
PFGWGEPQIUAZME-NXSMLHPHSA-N saralasin Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)C1=CC=C(O)C=C1 PFGWGEPQIUAZME-NXSMLHPHSA-N 0.000 description 2
229960004785 saralasin Drugs 0.000 description 2
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
239000007858 starting material Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
LDWBQGACJJOIKA-RHEFHGCGSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O LDWBQGACJJOIKA-RHEFHGCGSA-N 0.000 description 1
NQRKYASMKDDGHT-UHFFFAOYSA-N (aminooxy)acetic acid Chemical compound NOCC(O)=O NQRKYASMKDDGHT-UHFFFAOYSA-N 0.000 description 1
VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
229940123413 Angiotensin II antagonist Drugs 0.000 description 1
102400000344 Angiotensin-1 Human genes 0.000 description 1
101800000734 Angiotensin-1 Proteins 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108010077895 Sarcosine Proteins 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
229960003767 alanine Drugs 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
JTXJZBMXQMTSQN-UHFFFAOYSA-N amino hydrogen carbonate Chemical class NOC(O)=O JTXJZBMXQMTSQN-UHFFFAOYSA-N 0.000 description 1
125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
239000011260 aqueous acid Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000005660 chlorination reaction Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
125000001998 leucyl group Chemical group 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
206010038464 renal hypertension Diseases 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
238000007079 thiolysis reaction Methods 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/14—Angiotensins: Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Vascular Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

FI782250A 1977-07-18 1978-07-14 Foerfarande foer framstaellning av nya terapeutiskt anvaendbara peptider FI64140C (fi)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HURI000640		1977-07-18
HU77RI640A HU177133B (en)	1977-07-18	1977-07-18	Process for preparing angiotensin ii analogues containing alpha- amino-oxy-acid in position 1 with angiotensin ii antagonist activity

Publications (3)

Publication Number	Publication Date
FI782250A7 FI782250A7 (fi)	1979-01-19
FI64140B FI64140B (fi)	1983-06-30
FI64140C true FI64140C (fi)	1983-10-10

Family

ID=11001037

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI782250A FI64140C (fi)	1977-07-18	1978-07-14	Foerfarande foer framstaellning av nya terapeutiskt anvaendbara peptider

Country Status (24)

Country	Link
US (1)	US4179433A (cs)
JP (1)	JPS5835504B2 (cs)
AT (1)	AT361143B (cs)
AU (1)	AU518229B2 (cs)
BE (1)	BE869077A (cs)
CA (1)	CA1108124A (cs)
CH (1)	CH637915A5 (cs)
CS (1)	CS201014B2 (cs)
DD (1)	DD137220A5 (cs)
DE (1)	DE2831534C2 (cs)
DK (1)	DK319478A (cs)
ES (1)	ES471793A1 (cs)
FI (1)	FI64140C (cs)
FR (1)	FR2398050A1 (cs)
GB (1)	GB2001653B (cs)
HU (1)	HU177133B (cs)
IL (1)	IL55121A (cs)
IN (1)	IN149489B (cs)
NL (1)	NL7807676A (cs)
NO (1)	NO148031C (cs)
PL (1)	PL111979B1 (cs)
SE (1)	SE443790B (cs)
SU (1)	SU845773A3 (cs)
YU (1)	YU41431B (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU181008B (en) *	1980-01-18	1983-05-30	Richter Gedeon Vegyeszet	Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position
HU181009B (en) *	1980-01-18	1983-05-30	Richter Gedeon Vegyeszet	Process for preparing angiotensin-ii analogues with antagonictic activity containing in position 1 sarcosyl,hydroxyacetyl or l-alpha-aminoxy-propionyl group and in positiona 8 esteric group
HU191961B (en) *	1984-08-02	1987-04-28	Richter Gedeon Vegyeszet	Process for producing 1,5 and 8 substituted peptides of angiotenzin-ii antagonistic activity
US5182264A (en) *	1986-03-07	1993-01-26	Schering Corporation	Angiotensin II receptor blockers as antiglaucoma agents
US5036048A (en) *	1986-03-07	1991-07-30	Schering Corporation	Angiotensin II receptor blockers as antiglaucoma agents
US4772684A (en) *	1987-01-20	1988-09-20	Triton Biosciences, Inc.	Peptides affecting blood pressure regulation
TWI268138B (en) *	2000-05-11	2006-12-11	Kanebo Seiyaku Ltd	Composition containing peptide and electrolyte excretion enhancing substance, and food containing the same
AT508569A1 (de)	2009-07-23	2011-02-15	Affiris Ag	Pharmaceutical compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3886134A (en) *	1970-03-09	1975-05-27	Morton Norwich Products Inc	Analogues of angiotensin II
GB1320104A (en) *	1971-05-20	1973-06-13	Norwich Pharma Co	Hepta-and octapeptides
US3907762A (en) *	1971-12-27	1975-09-23	Univ Sherbrooke	Angiotensin{hd II {B position 8 analogs
HU167360B (cs) *	1972-08-25	1975-09-27
US3975365A (en) *	1975-01-27	1976-08-17	G. D. Searle & Co.	Inhibitory octapeptides angiotensin II
US3976770A (en) *	1975-02-10	1976-08-24	Francis Merlin Bumpus	Sar'-(OMe)Thr8 Angiotensin II as an angiotensin II antagonist

1977
- 1977-07-18 HU HU77RI640A patent/HU177133B/hu not_active IP Right Cessation
1978
- 1978-07-11 IL IL55121A patent/IL55121A/xx unknown
- 1978-07-11 US US05/923,681 patent/US4179433A/en not_active Expired - Lifetime
- 1978-07-13 CH CH762578A patent/CH637915A5/de not_active IP Right Cessation
- 1978-07-13 AU AU38008/78A patent/AU518229B2/en not_active Expired
- 1978-07-13 SE SE7807823A patent/SE443790B/sv not_active IP Right Cessation
- 1978-07-14 IN IN781/CAL/78A patent/IN149489B/en unknown
- 1978-07-14 CA CA307,439A patent/CA1108124A/en not_active Expired
- 1978-07-14 FI FI782250A patent/FI64140C/fi not_active IP Right Cessation
- 1978-07-14 DD DD78206733A patent/DD137220A5/xx unknown
- 1978-07-17 FR FR7821136A patent/FR2398050A1/fr active Granted
- 1978-07-17 NO NO782463A patent/NO148031C/no unknown
- 1978-07-17 DK DK319478A patent/DK319478A/da not_active Application Discontinuation
- 1978-07-17 CS CS784758A patent/CS201014B2/cs unknown
- 1978-07-17 SU SU782639399A patent/SU845773A3/ru active
- 1978-07-17 GB GB787830047A patent/GB2001653B/en not_active Expired
- 1978-07-17 ES ES471793A patent/ES471793A1/es not_active Expired
- 1978-07-17 YU YU1713/78A patent/YU41431B/xx unknown
- 1978-07-18 BE BE189343A patent/BE869077A/xx not_active IP Right Cessation
- 1978-07-18 AT AT518478A patent/AT361143B/de not_active IP Right Cessation
- 1978-07-18 PL PL1978208496A patent/PL111979B1/pl unknown
- 1978-07-18 NL NL7807676A patent/NL7807676A/xx not_active Application Discontinuation
- 1978-07-18 DE DE2831534A patent/DE2831534C2/de not_active Expired
- 1978-07-18 JP JP53087645A patent/JPS5835504B2/ja not_active Expired

Also Published As

Publication number	Publication date
PL208496A1 (pl)	1979-07-02
FI782250A7 (fi)	1979-01-19
NO148031B (no)	1983-04-18
YU41431B (en)	1987-06-30
FR2398050A1 (fr)	1979-02-16
BE869077A (fr)	1979-01-18
AT361143B (de)	1981-02-25
FR2398050B1 (cs)	1983-09-09
AU3800878A (en)	1980-01-17
DE2831534A1 (de)	1979-02-01
JPS5835504B2 (ja)	1983-08-03
NO782463L (no)	1979-01-19
JPS54119463A (en)	1979-09-17
GB2001653A (en)	1979-02-07
DD137220A5 (de)	1979-08-22
CA1108124A (en)	1981-09-01
AU518229B2 (en)	1981-09-17
NO148031C (no)	1983-07-27
SE7807823L (sv)	1979-01-19
FI64140B (fi)	1983-06-30
US4179433A (en)	1979-12-18
IN149489B (cs)	1981-12-26
YU171378A (en)	1983-01-21
IL55121A0 (en)	1978-09-29
ATA518478A (de)	1980-07-15
SU845773A3 (ru)	1981-07-07
HU177133B (en)	1981-07-28
NL7807676A (nl)	1979-01-22
PL111979B1 (en)	1980-09-30
CS201014B2 (en)	1980-10-31
IL55121A (en)	1981-09-13
GB2001653B (en)	1982-02-10
DE2831534C2 (de)	1982-02-18
SE443790B (sv)	1986-03-10
CH637915A5 (de)	1983-08-31
ES471793A1 (es)	1979-02-01
DK319478A (da)	1979-01-19

Legal Events

Date	Code	Title	Description
2004-08-31	MM	Patent lapsed	Owner name: RICHTER GEDEON VEGYESZETI GYOER R.T.

Publication	Publication Date	Title
US4522752A (en)	1985-06-11	Retro-inverso analogues of the bradykinin potentiating peptide BPP5a and methods for their preparation
US4261886A (en)	1981-04-14	Peptides having thymopoietin-like activity
HU181009B (en)	1983-05-30	Process for preparing angiotensin-ii analogues with antagonictic activity containing in position 1 sarcosyl,hydroxyacetyl or l-alpha-aminoxy-propionyl group and in positiona 8 esteric group
KR100360639B1 (ko)	2003-01-30	N-치환글리신함유브라디키닌길항제펩티드
JPH05508860A (ja)	1993-12-09	細胞接着制御環状化合物
JPS62129297A (ja)	1987-06-11	カルシトニン遺伝子関連ペプチド誘導体
EP0422937A1 (en)	1991-04-17	Fibrinogen receptor antagonists
US3947575A (en)	1976-03-30	Peptides as argiotensin converting enzyme inhibitors
US5834431A (en)	1998-11-10	Des-Arg9 -BK antagonists
FI64140B (fi)	1983-06-30	Foerfarande foer framstaellning av nya terapeutiskt anvaendbara peptider
FI64797B (fi)	1983-09-30	Foerfarande foer framstaellning av nya blodtrycknedsaettande peptider
US3976770A (en)	1976-08-24	Sar'-(OMe)Thr8 Angiotensin II as an angiotensin II antagonist
EP1997826A2 (en)	2008-12-03	Synthetic ligands for immunoglobulins and pharmaceutical compositions containing them
EP0101929B1 (en)	1986-01-22	Polypeptide-diesters, their production and use
US3925345A (en)	1975-12-09	(sar' 1',thr' 8'+9 angiotensin ii as an angiotensin antagonist
FI73225C (fi)	1987-09-10	Foerfarande foer framstaellning av terapeutiskt aktiva derivat av angiotensin-ii, vilka innehaoller i 8-staellningen -hydroxikarboxylsyragrupp.
JPH0631314B2 (ja)	1994-04-27	新規なゴナドリベリン誘導体
RU2010799C1 (ru)	1994-04-15	Производные пентапептидов
RU2119354C1 (ru)	1998-09-27	Способ направленного транспорта фармакологических препаратов путем их конъюгации с аргинил-глицил-аспартил (rgd) содержащими пептидами
DK155948B (da)	1989-06-05	Analogifremgangsmaade til fremstilling af pentapeptider til paavirkning af modningen af t-lymfocyter.
US3923769A (en)	1975-12-02	{8 N-Me-Ile{40 ,Ile{hu 8{b {9 -Angiotensin II as an angiotensin antagonist
SÜLI‐VARGHA et al.	1984	Synthesis of N‐(2‐chloroethyl)‐N‐nitrosocarbamoyl derivatives of biologically active polypeptide hormone fragments
JP2000503649A (ja)	2000-03-28	抗血栓剤および使用法
JPS6097998A (ja)	1985-05-31	ペプチド化合物